B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Signaling by LTK in cancer

REACTOME PATHWAY
Reactome: R-HSA-98426405 genes30 compounds

The Signaling by LTK in cancer pathway (Reactome ID: R-HSA-9842640) involves 5 genes and is affected by 30 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

MAPK1MAPK3PIK3CBPIK3R1PIK3R2

Compounds Affecting Signaling by LTK in cancer

#CompoundTargets HitStudies
1pictilisib25
2ly29400211
3Sirolimus300
4plumbagin [Supplementary Concept]300
5pd980597
6alsterpaullone12
7kenpaullone8
8isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from300
9Sorafenib300
10trametinib296
11withaferin300
12Wortmannin300
13alpelisib227
14tyrphostin ag 14784
15Clotrimazole296
16sp600125117
17fisetin78
18Progesterone299
192-Chloroadenosine 2-Chloroadenosine.300
20Benzalkonium Compounds299
21Calcimycin216
22daph2
23Diphenhydramine14
24ha10044
25Lithocholic Acid300
26Loratadine296
27trequinsin hydrochloride1
28torin 110
29Quercetin300
30Resveratrol298

About the Signaling by LTK in cancer Pathway

The Signaling by LTK in cancer pathway is catalogued in Reactome (ID: R-HSA-9842640) and involves 5 genes. In the BiohacksAI corpus, 30 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include MAPK1, MAPK3, PIK3CB, PIK3R1, PIK3R2.